Skip to search formSkip to main contentSkip to account menu

PD 0325901

Known as: PD325901, PD-0325901, PD 325901 
An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

BenzamidesDiphenylamine
NCIt Antineoplastic Agent Terminologyanalogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
High-risk neuroblastoma remains lethal in about 50% of patients despite multimodal treatment. Recent attempts to identify… 
2016
2016
KIT Exon 11 Codons 557–558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors
Purpose: KIT mutations, the most prevalent genetic event in gastrointestinal stromal tumors (GIST), are associated with malignant… 
2014
2014
Increased MAP Kinase Inhibition Enhances Epiblast-Specific Gene Expression in Bovine Blastocysts1
ABSTRACT Mammalian blastocysts comprise three distinct lineages, namely, trophoblast, hypoblast, and epiblast, which develop into… 
2012
2012
Simple and efficient derivation of mouse embryonic stem cell lines using differentiation inhibitors or proliferation stimulators.
The inhibition of endogenous differentiation-inducing signaling or the enhancement of growth capacity and viability of… 
2009
2009
1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) Enhances the Cytotoxicity of Combretastatin A4 Independently of Mitogen-Activated Protein Kinase Kinase
Combretastatin A4 (CA4) is a novel vascular-disrupting agent that has shown promising anticancer effects through its inhibition… 
Highly Cited
2008
Highly Cited
2008
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.
BACKGROUND We recently demonstrated inhibition of thyroid cancer cells by the MEK inhibitor CI-1040. The objective of this study… 
2007
2007
Pancreatic Cancer Cell Genetics and Signaling Response to Treatment Correlate with Efficacy of Gemcitabine-Based Molecular Targeting Strategies
IntroductionPancreatic cancer is a deadly cancer with limited sensitivity to gemcitabine. Molecular targeting of critical… 
Review
2006
Review
2006
Molecular Targets in Melanoma from Angiogenesis to Apoptosis
Angiogenesis is a hallmark of melanoma progression. Antiangiogenic agents have been infrequently tested in patients with advanced… 
Highly Cited
2005
Highly Cited
2005
A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer
3011 Background: Oral PD 0325901 is a potent inhibitor of the dual-specificity kinases, MEK1/2 (MAPK/ERK/Kinase), thereby… 
2005
2005
Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients
3066 Background: PD 0325901 is a potent and selective inhibitor of MEK1/2, (MAPK/ERK/KINASE) being developed for treatment of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)